FDA Approves Celgene’s Otezla for PsA
The federal Food and Drug Administration has given its nod to Otezla (apremilast) for the treatment of adults with active psoriatic arthritis (PsA).
The federal Food and Drug Administration has given its nod to Otezla (apremilast) for the treatment of adults with active psoriatic arthritis (PsA).
The selected companies will join MedTech Innovator's 2026 accelerator, where they'll receive mentorship from plastic surgeons and industry leaders while competing for funding.